KR102767739B1 - T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 - Google Patents

T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 Download PDF

Info

Publication number
KR102767739B1
KR102767739B1 KR1020217002231A KR20217002231A KR102767739B1 KR 102767739 B1 KR102767739 B1 KR 102767739B1 KR 1020217002231 A KR1020217002231 A KR 1020217002231A KR 20217002231 A KR20217002231 A KR 20217002231A KR 102767739 B1 KR102767739 B1 KR 102767739B1
Authority
KR
South Korea
Prior art keywords
methyl
dehydro
oxo
naphthyridine
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002231A
Other languages
English (en)
Korean (ko)
Other versions
KR20210024586A (ko
Inventor
유펜더 벨라파르티
루이스 에스. 추팍
체탄 파드마카르 다르네
민 딩
로버트 지. 젠틀레스
야종 후앙
만주나타 나라야나 라오 캄블레
스콧 더블유. 마틴
라주 만누리
이바르 엠. 맥도날드
리차드 이. 올슨
하시부르 라하만
프라사다 라오 잘라감
사우미아 로이
고피키샨 토누쿠누루
시바수다르 벨라이아
자야쿠마르 산카라 와리에르
샤오판 젱
존 에스. 토카르스키
비레슈와르 다스굽타
코타 라트나카르 레디
티루벤카담 라자
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20210024586A publication Critical patent/KR20210024586A/ko
Application granted granted Critical
Publication of KR102767739B1 publication Critical patent/KR102767739B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
KR1020217002231A 2018-06-27 2019-06-26 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 Active KR102767739B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690439P 2018-06-27 2018-06-27
US62/690,439 2018-06-27
US201962840459P 2019-04-30 2019-04-30
US62/840,459 2019-04-30
PCT/US2019/039135 WO2020006018A1 (en) 2018-06-27 2019-06-26 Substituted naphthyridinone compounds useful as t cell activators

Publications (2)

Publication Number Publication Date
KR20210024586A KR20210024586A (ko) 2021-03-05
KR102767739B1 true KR102767739B1 (ko) 2025-02-12

Family

ID=67439335

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217002231A Active KR102767739B1 (ko) 2018-06-27 2019-06-26 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물

Country Status (28)

Country Link
US (3) US10669272B2 (enExample)
EP (1) EP3814348B9 (enExample)
JP (1) JP7432532B2 (enExample)
KR (1) KR102767739B1 (enExample)
CN (1) CN112654621B (enExample)
AU (1) AU2019291794B2 (enExample)
BR (1) BR112020026681A2 (enExample)
CA (1) CA3104654A1 (enExample)
CL (1) CL2020003260A1 (enExample)
CY (1) CY1126280T1 (enExample)
DK (1) DK3814348T3 (enExample)
ES (1) ES2960754T3 (enExample)
FI (1) FI3814348T3 (enExample)
HR (1) HRP20231253T1 (enExample)
HU (1) HUE064531T2 (enExample)
IL (1) IL279728B2 (enExample)
LT (1) LT3814348T (enExample)
MX (1) MX2020013817A (enExample)
PE (1) PE20210469A1 (enExample)
PL (1) PL3814348T3 (enExample)
PT (1) PT3814348T (enExample)
RS (1) RS64641B1 (enExample)
SG (1) SG11202012972YA (enExample)
SI (1) SI3814348T1 (enExample)
SM (1) SMT202300466T1 (enExample)
TW (1) TW202019924A (enExample)
WO (1) WO2020006018A1 (enExample)
ZA (1) ZA202100555B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
MX2021013135A (es) 2019-04-29 2021-11-25 Solent Therapeutics Llc Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CR20220236A (es) 2019-11-28 2022-10-03 Bayer Pharma AG Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US20230064809A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
IL294085A (en) * 2019-12-19 2022-08-01 Bristol Myers Squibb Co Combinations of dgk inhibitors and checkpoint antagonists
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
BR112022012179A2 (pt) 2019-12-23 2022-09-06 Bristol Myers Squibb Co Compostos de quinazolina substituída úteis como ativadores de célula t
KR20220119456A (ko) * 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
AR120823A1 (es) * 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
BR112022012204A2 (pt) * 2019-12-23 2022-09-13 Bristol Myers Squibb Co Compostos de heteroarila substituída úteis como ativadores de célula t
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CN115697980B (zh) * 2020-04-24 2025-03-21 拜耳公司 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
WO2021258010A1 (en) * 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
KR102682398B1 (ko) * 2020-11-26 2024-07-05 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
CR20230415A (es) * 2020-11-30 2023-09-08 Kotobuki Pharmaceutical Co Ltd Compuesto de heteroarilcarboxamida
WO2022133083A1 (en) 2020-12-16 2022-06-23 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023150186A1 (en) * 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
JP2025507915A (ja) * 2022-03-01 2025-03-21 インシリコ メディスン アイピー リミティド ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用
EP4486741A4 (en) 2022-03-01 2026-04-08 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
US20250215014A1 (en) * 2022-03-31 2025-07-03 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US20240083898A1 (en) * 2022-08-15 2024-03-14 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
EP4583876A1 (en) 2022-09-08 2025-07-16 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
EP4661869A1 (en) 2023-02-06 2025-12-17 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators
CN116375654B (zh) * 2023-03-22 2024-12-31 湖北三峡实验室 一种由双甘肽制备2,5-二酮哌嗪的方法
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124604A1 (en) 2003-08-22 2005-06-09 Jagadish Sircar Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
US20080139551A1 (en) 2006-03-21 2008-06-12 Avanir Pharmaceuticals Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
EP1660087A2 (en) 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
WO2012142498A2 (en) 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
NO2694640T3 (enExample) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR089939A1 (es) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
CN107216325B (zh) 2016-03-22 2019-06-25 上海医药工业研究院 萘啶酮类化合物、及其制备方法和应用
CN110366550A (zh) 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
WO2018134885A1 (ja) 2017-01-17 2018-07-26 初実 田中 支援奨励システムおよび支援奨励方法
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
US20210238136A1 (en) 2018-06-07 2021-08-05 Daiichi Sankyo Company, Limited Azetidine derivative, and prodrug thereof
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
BR112020026637A2 (pt) 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
JP7561632B2 (ja) 2018-06-27 2024-10-04 キネタ， インコーポレイテッド プロテアソーム活性増強化合物
AU2019292207B2 (en) 2018-06-27 2022-06-30 Oscotec Inc. Pyridopyrimidinone derivatives for use as Axl inhibitors
WO2020006031A1 (en) 2018-06-27 2020-01-02 Biogen Ma Inc. Ask1 inhibiting agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124604A1 (en) 2003-08-22 2005-06-09 Jagadish Sircar Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
US20080139551A1 (en) 2006-03-21 2008-06-12 Avanir Pharmaceuticals Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Also Published As

Publication number Publication date
JP7432532B2 (ja) 2024-02-16
RS64641B1 (sr) 2023-10-31
DK3814348T3 (da) 2023-10-30
LT3814348T (lt) 2023-10-10
US20220324859A1 (en) 2022-10-13
ZA202100555B (en) 2022-07-27
US20200109140A1 (en) 2020-04-09
EP3814348B9 (en) 2023-11-01
ES2960754T3 (es) 2024-03-06
PT3814348T (pt) 2023-10-17
AU2019291794A1 (en) 2021-02-11
BR112020026681A2 (pt) 2021-04-06
US10669272B2 (en) 2020-06-02
EP3814348A1 (en) 2021-05-05
JP2021529191A (ja) 2021-10-28
TW202019924A (zh) 2020-06-01
WO2020006018A1 (en) 2020-01-02
SI3814348T1 (sl) 2023-10-30
IL279728B2 (en) 2023-07-01
CN112654621A (zh) 2021-04-13
SMT202300466T1 (it) 2024-01-10
KR20210024586A (ko) 2021-03-05
CY1126280T1 (el) 2026-02-25
MX2020013817A (es) 2021-03-09
SG11202012972YA (en) 2021-01-28
US10954238B1 (en) 2021-03-23
CA3104654A1 (en) 2020-01-02
FI3814348T3 (fi) 2023-09-22
HUE064531T2 (hu) 2024-04-28
EP3814348B1 (en) 2023-08-02
IL279728B1 (en) 2023-03-01
IL279728A (en) 2021-03-01
US11713316B2 (en) 2023-08-01
PL3814348T3 (pl) 2023-09-11
PE20210469A1 (es) 2021-03-08
HRP20231253T1 (hr) 2024-02-02
CN112654621B (zh) 2024-05-14
AU2019291794B2 (en) 2022-06-16
CL2020003260A1 (es) 2021-04-23

Similar Documents

Publication Publication Date Title
KR102767739B1 (ko) T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
US11584747B2 (en) Substituted pyridopyrimidinonyl compounds useful as T cell activators
KR102808367B1 (ko) Hpk1 억제제로서 유용한 이소푸라논 화합물
JP7373512B2 (ja) Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
CN114901660B (zh) 可作为t细胞活化剂的经取代双环化合物
JP7712274B2 (ja) Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体
WO2020023356A1 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EA043061B1 (ru) Замещенные нафтиридиноновые соединения, полезные в качестве активаторов т-клеток

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220624

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240604

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250205

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250210

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250210

End annual number: 3

Start annual number: 1

PG1601 Publication of registration